Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Phase III Study to Assess Efficacy and Safety of STALORAL 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-Dust Mites

Next Previous
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Phase III Study to Assess Efficacy and Safety of STALORAL 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-Dust Mites

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allergy immunotherapy (Primary)
  • Indications Allergic asthma; Hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes SA

Most Recent Events

  • 14 Oct 2015 Results published in the Allergy
  • 11 Oct 2011 Actual end date Jul 2009 added as reported by ClinicalTrials.gov.
  • 21 Jun 2010 Status changed from active, no longer recruiting to completed, according to a Stallergenes SA media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top